home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2875.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
33 lines
Document 2875
DOCN M94A2875
TI Association zidovudine and dipyridamole: a pharmacokinetic study.
DT 9412
AU Livrozet JM; Schrive I; Brunel F; Fournier F; Plasse JC; Touraine JL;
Hopital E. Herriot, Lyon, France.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):205 (abstract no. PB0250). Unique
Identifier : AIDSLINE ICA10/94369700
AB OBJECTIVE: Some studies reported dipyridamole potentiates antiviral
effect of zidovudine (ZDV) by inhibition of thymidine uptake and
phosphorylation. The aim of this study was to evaluate the effect of the
association ZDV and dipyridamole in HIV seropositive patients on ZDV
pharmacokinetic parameters (intracellular and plasmatic concentrations).
METHODS: Twelve patients were enrolled in this open cross over
pharmacokinetic study. Patients received 600 mg of ZDV by day during the
first seven days and 600 mg of ZDV and 450 mg of dipyridamole by day the
seven following days. We compared ZDV pharmacokinetic parameters (Cmax,
T max, half-life and AUC) on plasma and on total blood after treatment
by ZDV alone, and after treatment by ZDV and dipyridamole. RESULTS:
Results have shown no significant difference on ZDV plasmatic
concentrations between the 2 periods of treatment. Intracellular
concentrations are actually performed. DISCUSSION: The association of
ZDV and dipyridamole could reduce ZDV side effects and treatment costs.
DE Dipyridamole/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS/ THERAPEUTIC USE
Drug Interactions Drug Therapy, Combination Half-Life Human HIV
Infections/BLOOD/*DRUG THERAPY Zidovudine/ADMINISTRATION &
DOSAGE/*PHARMACOKINETICS/THERAPEUTIC USE CLINICAL TRIAL MEETING
ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).